VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss German biotech company focused on develo - James Burnham - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-07-12 04:22:18 Medicine Clinical medicine Cancer treatments Immunology Oncology Immunotherapy Virotherapy Glioblastoma Chemotherapy Immune system Cancer immunotherapy ALECSAT		VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo Add to Reading List Source URL: sunstone.eu Download Document from Source Website File Size: 362,33 KB Share Document on Facebook

	CURTANA PHARMACEUTICALS AWARDED NIH SMALL BUSINESS TECHNOLOGY TRANSFER GRANT TO ADVANCE GLIOBLASTOMA CANCER THERAPY SAN DIEGO, CA – October 1, 2014 – Curtana Pharmaceuticals, a privately-held, preclinical stage pharm DocID: 1uww2 - View Document
	Applica tion N ot e Poseidon Select™ Real-Time Imaging of Nanoparticle Movement within Glioblastoma Cells DocID: 1sZTi - View Document
	LNCSRobust Skull Stripping of Clinical Glioblastoma Multiforme Data DocID: 1rLcB - View Document
	VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo DocID: 1rgZo - View Document
	Lettre d’information du réseau GCO - Spéciale ASCOLes Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (Ameri DocID: 1qX2r - View Document